ES2084045T3 - Bacterias que albergan vectores de expresion que codifican el factor neurotrofico ciliar humano (h-cntf), su uso en la produccion de h-cntf, anticuerpos para h-cntf y el uso de h-cntf en el tratamiento medico. - Google Patents

Bacterias que albergan vectores de expresion que codifican el factor neurotrofico ciliar humano (h-cntf), su uso en la produccion de h-cntf, anticuerpos para h-cntf y el uso de h-cntf en el tratamiento medico.

Info

Publication number
ES2084045T3
ES2084045T3 ES90917018T ES90917018T ES2084045T3 ES 2084045 T3 ES2084045 T3 ES 2084045T3 ES 90917018 T ES90917018 T ES 90917018T ES 90917018 T ES90917018 T ES 90917018T ES 2084045 T3 ES2084045 T3 ES 2084045T3
Authority
ES
Spain
Prior art keywords
cntf
nucleic acid
acid sequences
relates
variety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90917018T
Other languages
English (en)
Inventor
Piotr Masiakowski
Vivien Wong
Nikos Panayotatos
Hans Friedrich Erwin Thoenen
Kurt A Stockli-Rippstein
Michael Sendtner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Regeneron Pharmaceuticals Inc
Original Assignee
Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2084045(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV, Regeneron Pharmaceuticals Inc filed Critical Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Application granted granted Critical
Publication of ES2084045T3 publication Critical patent/ES2084045T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A SECUENCIAS ACIDAS NUCLEICAS QUE CODIFICAN UN FACTOR NEUROTROFICO CILIAR (CNTF) Y A LAS PROTEINAS, PEPTIDOS Y DERIVADOS PRODUCIDOS A PARTIR DE LAS MISMAS. EN VARIAS APLICACIONES DE LA INVENCION, LAS SECUENCIAS ACIDAS NUCLEICAS, PROTEINAS Y PEPTIDOS DE LA INVENCION PUEDEN SER UTILIZADAS EN EL TRATAMIENTO DE VARIAS ENFERMEDADES Y TRASTORNOS NEUROLOGICOS, INCLUIDA LA ENFERMEDAD DE ALZHEIMER. EN UNA APLICACION ESPECIFICA DE LA INVENCION, EL CNTF PUEDE SER UTILIZADO PARA SOPORTAR EL CRECIMIENTO DE NEURONAS DE LA MEDULA ESPINAL, PROPORCIONANDO ASI UN METODO PARA EL TRATAMIENTO DE MALES EN LA MEDULA ESPINAL OCASIONADOS POR UNA INFECCION TRAUMATICA, INFECCION, DEFICIENCIA NUTRICIONAL O AGENTES TOXICOS. LA INVENCION TAMBIEN SE REFIERE A UN METODO NUEVO PARA PRODUCIR UN CNTF SUSTANCIALMENTE PURO. LA INVENCION TAMBIEN SE REFIERE A COMPUESTOS FARMACEUTICOS QUE CONTIENEN CANTIDADES EFECTIVAS DE PRODUCTOS DE GENES DE CNTF QUE PUEDEN SER UTILIZADOS EN EL DIAGNOSTICO Y TRATAMIENTODE VARIAS ENFERMEDADES Y TRASTORNOS NEUROLOGICOS. LA INVENCION SE REFIERE AL CONTROL SECUENCIAL CLONING Y EXPRESION DE CNTF Y PROPORCIONA, POR PRIMERA VEZ, UN MEDIO PARA PRODUCIR UN CNTF HUMANO UTILIZANDO SECUENCIAS ACIDAS NUCLEICAS QUE CODIFICAN UN CNTF HUMANO. ADEMAS, LAS SECUENCIAS ACIDAS NUCLEICAS DEL CNTF DE LA INVENCION PUEDEN SER UTILIZADAS PARA IDENTIFICAR SECUENCIAS ACIDAS NUCLEICAS QUE CODIFICAN EL CNTF O MOLECULAS HOMOLOGAS DEL CNTF EN UNA GRAN VARIEDAD DE ESPECIES Y TEJIDOS.
ES90917018T 1989-09-15 1990-09-14 Bacterias que albergan vectores de expresion que codifican el factor neurotrofico ciliar humano (h-cntf), su uso en la produccion de h-cntf, anticuerpos para h-cntf y el uso de h-cntf en el tratamiento medico. Expired - Lifetime ES2084045T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40817289A 1989-09-15 1989-09-15
US42951789A 1989-10-31 1989-10-31
US57065190A 1990-08-20 1990-08-20

Publications (1)

Publication Number Publication Date
ES2084045T3 true ES2084045T3 (es) 1996-05-01

Family

ID=27410749

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90917018T Expired - Lifetime ES2084045T3 (es) 1989-09-15 1990-09-14 Bacterias que albergan vectores de expresion que codifican el factor neurotrofico ciliar humano (h-cntf), su uso en la produccion de h-cntf, anticuerpos para h-cntf y el uso de h-cntf en el tratamiento medico.

Country Status (11)

Country Link
US (1) US6602687B1 (es)
EP (1) EP0448707B1 (es)
JP (2) JPH05199879A (es)
AT (1) ATE130365T1 (es)
AU (1) AU705371B2 (es)
CA (1) CA2040404A1 (es)
DE (1) DE69023637T2 (es)
ES (1) ES2084045T3 (es)
IE (1) IE903130A1 (es)
LV (1) LV10308A (es)
WO (1) WO1991004316A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141856A (en) * 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
AT405835B (de) * 1989-01-05 1999-11-25 Synergen Inc Aufgereinigter ziliärer neurotropher faktor
IL98304A (en) * 1990-06-01 2008-08-07 Regeneron Pharma The ciliary neurotrophic factor receptor
IT1247150B (it) * 1991-01-21 1994-12-12 Fidia Spa Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.
RU94016525A (ru) * 1991-07-10 1996-06-10 Ридженерон Фармасьютикалз Способы лечения заболеваний двигательных нейронов
FI940302A7 (fi) * 1991-07-23 1994-01-21 Syntex Synergen Neuroscience Joint Siliaarisen neurotrofisen rekombinanttifaktorin ja C-päästä lyhentynee n siliaarisen neurotrofisen faktorin puhdistus ja menetelmät perifeeri sten hermovaurioiden hoitamiseksi
US5593857A (en) * 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
CA2119580A1 (en) * 1991-10-01 1993-04-15 George Cachianes Production of gpa neurotrophic factor
WO1993010233A1 (en) * 1991-11-11 1993-05-27 Fidia S.P.A. Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
DE69334238D1 (de) * 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
CA2155540A1 (en) * 1993-02-08 1994-08-18 Frank Collins Methods for treating amyotrophic lateral sclerosis with cntf
ZA941729B (en) * 1993-03-12 1994-10-13 Max Planck Gesellschaft Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5).
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
EP0632008B1 (en) 1993-06-01 1998-02-04 Ono Pharmaceutical Co., Ltd. Pentanoic acid derivatives
US6143714A (en) * 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
ES2301178T3 (es) 1996-04-05 2008-06-16 Novartis Vaccines & Diagnostic Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
FR2753379B1 (fr) * 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
US6313089B1 (en) * 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
EP0999270A1 (en) * 1998-10-09 2000-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of regulating SMN gene expression
EP1365785A2 (en) * 2000-05-24 2003-12-03 Regeneron Pharmaceuticals, Inc. Use of ciliary neurotrophic factor
ATE503845T1 (de) * 2001-12-10 2011-04-15 Novartis Pharma Gmbh Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
JP2005073592A (ja) * 2003-09-01 2005-03-24 Yukiguni Maitake Co Ltd マイタケ由来のレクチンをコードする遺伝子
EP2009103A1 (en) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophic peptides
US8592374B2 (en) 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
AU2014362722B2 (en) * 2013-12-11 2021-06-10 Riken Method for manufacturing ciliary marginal zone-like structure
US20210121534A1 (en) * 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
AU2019290582A1 (en) * 2018-06-19 2021-01-28 Cella Therapeutics, Llc Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease
CN115119501A (zh) * 2019-12-18 2022-09-27 细胞疗法有限责任公司 包含神经营养剂、凋亡信号传导片段抑制剂（FAS）或FAS配体（FASL）抑制剂、肿瘤坏死因子-α（TNF-α）或TNF受体抑制剂、线粒体肽、寡核苷酸、趋化因子抑制剂或半胱氨酸-天冬氨酸蛋白酶抑制剂的药物递送系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5141856A (en) 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
US4997929A (en) 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
WO1990010647A1 (en) * 1989-03-15 1990-09-20 The Regents Of The University Of California Purified ciliary neurotrophic factor
EP0446931A1 (en) * 1990-03-14 1991-09-18 FIDIA S.p.A. Human ciliary neuronotrophic factor, DNA sequence encoding the factor, and production of the factor by recombinant technology

Also Published As

Publication number Publication date
US6602687B1 (en) 2003-08-05
LV10308A (lv) 1994-10-20
AU6740290A (en) 1991-04-18
WO1991004316A3 (en) 1991-04-18
EP0448707A1 (en) 1991-10-02
CA2040404A1 (en) 1991-03-16
JP2001354697A (ja) 2001-12-25
ATE130365T1 (de) 1995-12-15
JPH05199879A (ja) 1993-08-10
AU705371B2 (en) 1999-05-20
EP0448707B1 (en) 1995-11-15
DE69023637D1 (de) 1995-12-21
WO1991004316A2 (en) 1991-04-04
EP0448707A4 (en) 1992-11-19
IE903130A1 (en) 1991-03-27
DE69023637T2 (de) 1996-10-17

Similar Documents

Publication Publication Date Title
LV10308A (lv) Ciliarais neirotropais faktors
Obal Jr et al. Interleukin 1 alpha and an interleukin 1 beta fragment are somnogenic
DE3855921D1 (de) Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein
NO905264L (no) Fremgangsmaate for fremstilling av biologisk aktivt protein
BG100236A (en) Sheared keratiocytic growth factor (kgf) of increased biological activity
ATE17858T1 (de) Angiotropine aus leukozyten und entzuendeten geweben: eine neue klasse von natuerlichen chemotropischen und mitogenen proteinen fuer die spezifische induktion des gesteuerten wachstums von blutgefaessen, fuer neue gefaessbildung von geweben und fuer die morphogenese von blutgefaessverzweigungen; verfahren zu ihrer biotechnischen herstellung und pharmazeutische zusammensetzungen.
DE3584120D1 (de) Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
FI912104A0 (fi) Neurotrofisk faktor haerledd fraon hjaerna.
DK17986D0 (da) Oligopeptider samt mellemprodukter og fremgangsmaade til fremstilling deraf
FI103506B1 (fi) Menetelmä syklisten aminohappojohdannaisten valmistamiseksi ja menetelmässä käytettävä välituote
DE69737740D1 (de) GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine
NO960309L (no) Agonister og antagonister for humaninterleukin-10
JPH05504566A (ja) 生物学的活性を有するペプチドを使用した創傷処置方法
WO1995025171A3 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
DE60126495D1 (de) Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
ATE513900T1 (de) Herstellung und verwendung von humanen cd124 und cd116 positiven tumorzelllinien zur herstellung von allogenen oder semi-allogenen immuntherapeutika
EP0458673B1 (en) Growth-inhibitory factor and cDNA coding for growth inhibitory factor
EP0238275A3 (en) Recombinant product
PT990000E (pt) Factor 3 de crescimento do tecido conjuntivo
GR900100691A (el) Νευροτροφικός παράγοντας ακτινωτού.
WO1991006560A1 (de) Quervernetzte tumor-nekrose-faktoren
ATE111522T1 (de) Methode zur herstellung von rekombinantem menschlichem beta-interleukin-1 in homogener form.
Schreiber Synthesis, structure and biological investigations of β-peptides
WO1997006258A3 (de) cDNA-SEQUENZ UND DARAUS ABGELEITETE AMINOSÄURESEQUENZ DES VORLÄUFERPROTEINS VON HUMANEM GCAP-II/UROGUANYLIN SOWIE AMINOSÄURESEQUENZ DES IM HUMANEN BLUT ZIRKULIERENDEN FRAGMENTES

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 448707

Country of ref document: ES